
KOD Stock Forecast & Price Target
KOD Analyst Ratings
Bulls say
Kodiak Sciences Inc has demonstrated robust clinical efficacy through its product candidates, particularly KSI-101, which has shown significant vision gains in patients with over 90% achieving retinal dryness by Week 8. Additionally, positive data from the GLOW2 study for tarcocimab tedromer indicates a substantial increase in the probability of success (POS) in treating diabetic retinopathy (from 35% to 70%) and wet AMD (from 35% to 60%), highlighting the potential for effective therapeutic solutions in high-prevalence retinal diseases. Furthermore, the ongoing favorable reception from key opinion leaders regarding novel retinal therapies along with the solid execution of pivotal trials are factors contributing to an overall positive outlook on the company's future performance.
Bears say
Kodiak Sciences Inc. has faced significant challenges with its developmental candidates, notably the failures of the Phase 3 GLEAM and GLIMMER trials in diabetic macular edema (DME), and the Phase 2b/3 DAZZLE trial in wet age-related macular degeneration (AMD), which hinder the company's credibility and potential market position. The company faces risks related to failing to meet peak commercial revenue estimates, exacerbated by uncertainties in market size, penetration rates, and pricing strategies for its products, particularly Tarcocimab tedromer. Additionally, there are concerns regarding Kodiak Sciences's ability to secure adequate capital resources to fund ongoing operations and the development of its therapeutic pipeline, which further compounds the negative outlook on its financial stability and growth prospects.
This aggregate rating is based on analysts' research of Kodiak Sciences Inc and is not a guaranteed prediction by Public.com or investment advice.
KOD Analyst Forecast & Price Prediction
Start investing in KOD
Order type
Buy in
Order amount
Est. shares
0 shares